Creative Planning’s Carisma Therapeutics CARM Stock Holding History

Creative Planning’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-935	Closed	-$49K	–	2153
2021 Q1	$49K	Hold	935	–	–	﹤0.01%	2354
2020 Q4	$25K	Hold	935	–	–	﹤0.01%	2165
2020 Q3	$26K	Hold	935	–	–	﹤0.01%	1960
2020 Q2	$13K	Hold	935	–	–	﹤0.01%	1861
2020 Q1	$10K	Hold	935	–	–	﹤0.01%	1765
2019 Q4	$19K	Buy	935 +275	+42%	+$6.32K	﹤0.01%	1880
2019 Q3	$15K	Hold	660	–	–	﹤0.01%	1876
2019 Q2	$20K	Hold	660	–	–	﹤0.01%	1890
2019 Q1	$14K	Hold	660	–	–	﹤0.01%	1861
2018 Q4	$19K	Buy	660 +40	+6%	+$1.28K	﹤0.01%	1791
2018 Q3	$27K	Buy	+620	New	+$24.2K	﹤0.01%	1927

Other funds holding CARM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning's CARM Position: Q2 2021 in Review

Creative Planning sold out of Carisma Therapeutics (CARM) in Q2 2021, closing a stake of 935 shares — an estimated $49K sold.

Creative Planning first reported a position in CARM in Q3 2018 and held it in 11 quarters. The position peaked at $49K in Q1 2021. 105 funds tracked by Wall St. Rank hold CARM as of Q2 2021.

Creative Planning reported no remaining Carisma Therapeutics position as of Q2 2021 after selling out during the quarter.
Creative Planning sold 935 Carisma Therapeutics shares in Q2 2021, an estimated $49K.
Creative Planning first reported a position in Carisma Therapeutics in Q3 2018 and held it in 11 quarters.
Creative Planning's Carisma Therapeutics position peaked at $49K in Q1 2021.
105 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2021.

Based on Creative Planning's 13F filing for Q2 2021, filed 4 Aug 2021.